October 18-20 | Tucson, AZ

The Research Institution GAP Fund and Accelerator Program Summit

Visit Event Site

AstraZeneca signs huge deal with UK start-up

GET GAP Insights

Join Us

October 16-17, 2025 / Seattle, WA

The annual summit for research institution gap fund and accelerator programs, including proof of concept programs, startup accelerators, and university venture funds

Visit event site

The Story

Pharma giant AstraZeneca has signed a huge deal with a UK start-up to create treatments for diabetes and other autoimmune diseases.

The FTSE 100 firm will team up with London-based Quell Therapeutics to collaborate on research and the licensing of any new medicines.

The aim is to develop treatments for Type 1 diabetes and inflammatory bowel disease through the use of genetically engineered ‘regulatory T-cells’ – ‘Tregs’ for short.

 

Full story: AstraZeneca in deal with start-up to fight diabetes | This is Money

JOIN THE COMMUNITY

Get the Report

More GAP News

Consortium For Gap Fund and Accelerator ProgramS

Explore Institutional Participation

The Consortium provides a dedicated, institutional coordinating forum for collective insight, program refinement, and structured engagement with aligned commercial, investment, and philanthropic partners.

GAP are an interdependent institutional innovation and capital strategy that includes:

  • Translational research

  • Proof of concept programs

  • Startup accelerators

  • University venture funds

Get GAP Insights